Intensification of GVHD prophylaxis with low-dose ATG-F before allogeneic PBSC transplantation from HLA-identical siblings in adult patients with hematological malignancies: Results from a retrospective analysis

Bone Marrow Transplantation

Volumn 47, Issue 8, 2012, Pages 1105-1111

  Bonifazi, F ^a   Bandini, G ^a   Arpinati, M ^a   Tolomelli, G ^a   Stanzani, M ^a   Motta, M R ^a   Rizzi, S ^a   Giudice, V ^a   Dan, E ^a   Massari, E ^a   Tazzari, P ^a   Bontadini, A ^a   Pagliaro, P ^a   Baccarani, M ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

ATG; GVHD; hematopoietic SCT; sibling transplants; TRM

Indexed keywords

CYCLOSPORIN A; METHOTREXATE; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER GROWTH; CANCER RELAPSE; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; FEMALE; HEMATOLOGIC MALIGNANCY; HLA MATCHING; HUMAN; INCIDENCE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROPHYLAXIS; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; SIBLING;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ANTILYMPHOCYTE SERUM; CHRONIC DISEASE; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RETROSPECTIVE STUDIES; SIBLINGS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84864882229     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2011.225     Document Type: Article

References (43)

1. Bensinger WI, Weaver CH, Appelbaum FR, Rowley S, Demirer T, Sanders J et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1995; 85: 1655-1658.
2. Kö rbling M, Przepiorka D, Huh YO, Engel H, van Besien K, Giralt S et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 1995; 85: 1659-1665.
3. Schmitz N, Dreger P, Suttorp M, Rohwedder EB, Haferlach T, Lö ffler H et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 1995; 85: 1666-1672.
4. Gratwohl A, Baldomero H, Schwendener A, Gratwohl M, Apperley J, Frauendorfer K et al. The EBMT activity survey 2008 impact of team size, team density and new trends. Bone Marrow Transplant 2011; 46: 1-18.
5. Bensinger WI, Clift R, Martin P, Appelbaum FR, Demirer T, Gooley T et al. Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation. Blood 1996; 88: 2794-2800. (Pubitemid 26327536)
6. Schmitz N, Bacigalupo A, Hasenclever D, Nagler A, Gluckman E, Clark P et al. Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1998; 21: 995-1003. (Pubitemid 28230663)
7. Vigorito AC, Azevedo WM, Marques JF, Azevedo AM, Eid KA, Aranha FJ et al. A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies. Bone Marrow Transplant 1998; 22: 1145-1151. (Pubitemid 29021122)
8. Blaise D, Kuentz M, Fortainer C, Bourhis JH, Milpied N, Sutton L et al. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patient with early-stage leukemia: a report from the Socié té Francaise de Greffe de Moelle. J Clin Oncol 2000; 18: 537-546. (Pubitemid 30078535)
9. Champlin RE, Schmitz N, Horowitz MM, Chapuis B, Chopra R, Cornelissen JJ et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. Blood 2000; 95: 3702-3709. (Pubitemid 30412840)
10. Couban S, Simpson D, Barnett MJ, Bredeson C, Hubesch L, Howson-Jan K et al. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 2002; 100: 1525-1531. (Pubitemid 34925122)
11. Storek J, Gooley T, Siadak M, Bensinger WI, Maloney DG, Chauncey TR et al. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. Blood 1997; 90: 4705-4709. (Pubitemid 28007182)
12. Vigorito AC, Marques Junior JF, Aranha FJ, Oliveira GB, Miranda EC, De Souza CA. A randomized, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematologic malignancies: an update. Haematologica 2001; 86: 665-666. (Pubitemid 32601115)
13. Mohty M, Kuentz M, Michallet M, Bourhis JH, Milpied N, Sutton L et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: longterm results of a randomized study. Blood 2002; 100: 3128-3134. (Pubitemid 35217059)
14. Schmitz N, Eapen M, Horowitz MM, Zhang MJ, Klein JP, Rizzo JD et al. Long-term outcome of patients given transplants of mobilized blood or bone marrow: a report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. Blood 2006; 106: 4288-4290. (Pubitemid 44913306)
15. Friedrichs B, Tichelli A, Bacigalupo A, Russell NH, Ruutu T, Shapira MY et al. Longterm out come and late effects in patients transplanted with mobilised blood or bone marrow: a randomised trial. Lanc Oncol 2010; 11: 331-338.
16. Cutler C, Giri S, Jevapalan S, Paniagua D, Viswanathan A, Antin JH. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stemcell and bone marrow transplantation: a meta-analysis. J Clin Oncol 2001; 19: 3685-3691. (Pubitemid 32786281)
17. Stem Cell Trialists' Collaborative Group. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol 2005; 23: 5074-5087.
18. Lee SJ, Kim HT, Ho VT, Cutler C, Alyea EP, Soiffer RJ et al. Quality of life associated with acute and chronic graft-versus-host disease. Bone Marrow Transplant 2006; 38: 305-310. (Pubitemid 44203780)
19. Eapen M, Logan BR, Confer DL, Haagenson M, Wagner JE, Weisdorf DJ et al. Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival. Biol Blood Marrow Transplant 2007; 13: 1461-1468. (Pubitemid 350091382)
20. Koca E, Champlin RE. Peripheral blood progenitor cell or bone marrow transplantation: controversy remains. Curr Opin Oncol 2008; 20: 220-226. (Pubitemid 351317411)
21. Pidala J, Anasetti C, Kharfan-Dabaja MA, Cutler C, Sheldon A, Djulbegovic B. Decision analysis of peripheral blood versus bone marrow hematopoietic stem cells for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2009; 15: 1415-1421.
22. Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors. A randomised, open-label, multicentre phase 3 trial. Lancet Oncol 2009; 10: 855-864.
23. Bonifazi F, Bandini G, Stanzani M, Palandri F, Giannini B, Arpinati M et al. In vivo T-cell depletion with low-dose ATG is effective in reducing cGVHD after peripheral blood stem cell myeloablative sibling transplants in CML: results from a prospective phase II study. Bone Marrow Transplant 2005; 35: 1025-1026. (Pubitemid 40711842)
24. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol 1983; 1: 710-719. (Pubitemid 14202071)
25. Gratwohl A, Schwendener A, Baldomero H, Gratwohl M, Apperley J, Niederwieser D et al. Changes in the use of hematopoietic stem cell transplantation: a model for diffusion of medical technology. Haematologica 2010; 95: 637-643.
26. Kroger N, Zabelina T, Krü ger W, Renges H, Stute N, Rischewski J et al. Graft-versushost disease. In vivo T cell depletion with pretransplant antithymocyte globulin reduces graft-versus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors. Bone Marrow Transplant 2002; 29: 683-689. (Pubitemid 34591312)
27. Basara N, Baurmann H, Kolbe K, Yaman A, Labopin M, Burchardt A et al. Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia: results from the multicenter German cooperative study group. Bone Marrow Transplant 2005; 35: 1011-1018. (Pubitemid 40711839)
28. Kim HJ, Min WS, Cho BS, Eom KS, Kim YJ, Min CK et al. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transplant 2009; 15: 704-717.
29. Chen XH, Zhang C, Zhang X, Gao L, Gao L, Kong PY et al. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies. Biol Blood Marrow Transplant 2009; 15: 266-273.
30. Gratwohl A, Brand R, Apperley J, Biezen Av A, Bandini G, Devergie A et al. Graft-versus-host disease and outcome in HLA-identical sibling transplantation for chronic myeloid leukemia. Blood 2002; 100: 3877-3886. (Pubitemid 35396852)
31. Bensiger W. Individual patient data meta-analysis of allogeneic peripheral blood stem cell transplant vs bone marrow transplant in the management of haematological malignancies: indirect assessment of the effect of day 11 methotrexate administration. Bone Marrow Transplant 2006; 38: 539-546.
32. Baron F, Sandmaier BM, Storer BE, Maris MB, Langston AA, Lange T et al. Extended mycophenolate mofetil and shortened cyclosporine failed to reduce graft-vs-host disease after unrelated hematopoietic cell transplantation with nonmyeloablative conditioning. Biol Blood Marrow Transplant 2007; 13: 1041-1048. (Pubitemid 47215560)
33. Cornelissen JJ, Van der Holt B, Petersen EJ, Vindelov L, Russel CA, Hö glund M et al. A randomized multicenter comparison of CD34-selected progenitor cells from bone marrow in recipients of HLA-identical allogeneic transplants for haematological malignancies. Exp Hematol 2003; 31: 1-10.
34. Ho VT, Kim HT, Li S, Hochberg EP, Cutler C, Lee SJ et al. Partial CD8+ T-cell depletion of allogeneic peripheral blood stem cell transplantation is insufficient to prevent graft-versus-host disease. Bone Marrow Transplant 2004; 34: 987-994. (Pubitemid 39600117)
35. Mengarelli A, Iori AP, Romano A, Cerretti R, Cerilli L, De Propris MS et al. One-year cyclosporine prophylaxis reduces the risk of developing extensive chronic graftversus-host disease after allogeneic peripheral blood stem cell transplantation. Haematologica 2003; 88: 315-323. (Pubitemid 36358720)
36. Cutler C, Antin JH. Sirolimus immunosuppression for graft-versus-host disease prophylaxis and therapy: an update. Curr Opin Hematol 2010; 17: 500-504.
37. Frassoni F. Anti-T-cell globulin: an essential ingredient for haematopoietic cell transplantation? Lancet Oncol 2009; 10: 839.
38. Perkins J, Field T, Kim J, Kharfan-Dabaja MA, Fernandez H, Ayala E et al. A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-vs-host disease prophylaxis. Biol Blood Marrow Transplant 2010; 16: 937-947.
39. Zohren F, Schroeder T, Czibere A, Fenk R, Bruns I, Kondakci M et al. Tacrolimus and mycofenolate mofetil as GvHD prophylaxis following nonmyeloablative conditioning and unrelated hematopoietic SCT for adult patients with advanced hematologic diseases. Bone Marrow Transplant 2011; 46: 747-755.
40. Remberger M, Svan BM, Hentschke P, Lö fgren C, Ringdén O. Effect on cytokine release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation. Bone Marrow Transplant 1999; 24: 823-830. (Pubitemid 29500340)
41. Soiffer RJ, LeRademacher J, Ho V, Kan F, Artz A, Champlin RE et al. Impact of immune modulation with anti-T-cell antibodies on the out come of reducedintensity allogeneic stem cell transplantation for hematologic malignancies. Blood 2011; 117: 6963-6970.
42. Pistillo MP, Tazzari PL, Bonifazi F, Bandini G, Kato T, Matsui T et al. Detection of a novel specificity (CTLA-4) in ATG/TMG globulins and sera from ATG-treated leukemic patients. Transplantation 2002; 73: 1295-1302. (Pubitemid 34454279)
43. Gratwohl A, Stern M, Brand R. Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer 2009; 115: 4715-4726.